Sofinnova Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-322,471
| Closed | -$32.9M | – | 78 |
|
|
2023
Q2 | $32.9M | Sell |
322,471
-305,212
| -49% | -$28.9M | 2.15% | 16 |
|
|
2023
Q1 | $57.1M | Sell |
627,683
-364,346
| -37% | -$21.4M | 3.65% | 7 |
|
|
2022
Q4 | $37.7M | Buy |
992,029
+173,653
| +21% | +$5.98M | 2.24% | 13 |
|
|
2022
Q3 | $20.6M | Buy |
818,376
+34,525
| +4% | +$957K | 1.2% | 19 |
|
|
2022
Q2 | $23.8M | Buy |
783,851
+181,306
| +30% | +$5.41M | 1.98% | 14 |
|
|
2022
Q1 | $19.7M | Buy |
+602,545
| New | +$17.9M | 1.5% | 17 |
|
|
2021
Q4 | – | Sell |
-157,488
| Closed | -$15.8M | – | 82 |
|
|
2021
Q3 | $15.8M | Buy |
157,488
+77,887
| +98% | +$9.13M | 0.94% | 24 |
|
|
2021
Q2 | $11.3M | Sell |
79,601
-158,919
| -67% | -$17.9M | 0.65% | 37 |
|
|
2021
Q1 | $23.8M | Buy |
238,520
+89,583
| +60% | +$10.4M | 1.43% | 19 |
|
|
2020
Q4 | $18.4M | Buy |
148,937
+80,322
| +117% | +$10.6M | 1.1% | 21 |
|
|
2020
Q3 | $6.68M | Buy |
68,615
+55,580
| +426% | +$6.94M | 0.5% | 38 |
|
|
2020
Q2 | $2.03M | Buy |
+13,035
| New | +$1.98M | 0.13% | 64 |
|
|
2019
Q4 | – | Sell |
-148,669
| Closed | -$11.9M | – | 75 |
|
|
2019
Q3 | $11.9M | Buy |
148,669
+33,133
| +29% | +$2.81M | 1.08% | 24 |
|
|
2019
Q2 | $10.9M | Buy |
115,536
+50,505
| +78% | +$4.36M | 1% | 25 |
|
|
2019
Q1 | $5.56M | Sell |
65,031
-92,953
| -59% | -$7.72M | 0.54% | 37 |
|
|
2018
Q4 | $8.86M | Buy |
+157,984
| New | +$9.65M | 1.1% | 22 |
|
|
2018
Q3 | – | Sell |
-89,909
| Closed | -$3.14M | – | 66 |
|
|
2018
Q2 | $3.14M | Buy |
89,909
+60,526
| +206% | +$1.84M | 0.36% | 45 |
|
|
2018
Q1 | $603K | Buy |
+29,383
| New | +$756K | 0.1% | 27 |
|
Other funds holding RETA
Sofinnova Investments's RETA Position: Q3 2023 in Review
Sofinnova Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 322,471 shares — an estimated $32.9M sold.
Sofinnova Investments first reported a position in RETA in Q1 2018 and held it in 18 quarters. The position peaked at $57.1M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Sofinnova Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Sofinnova Investments sold 322,471 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $32.9M.
- Sofinnova Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 18 quarters.
- Sofinnova Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $57.1M in Q1 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Sofinnova Investments's 13F filing for Q3 2023, filed 14 Nov 2023.